Skip to main content
Erschienen in: Current Treatment Options in Psychiatry 3/2015

01.09.2015 | Mood Disorders (S Frangou, Section Editor)

Treatment Options in Bipolar Disorder: Lessons from Population-Based Registers with Focus on Lithium

verfasst von: Lars Vedel Kessing, MD, DMSc

Erschienen in: Current Treatment Options in Psychiatry | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Opinion statement

Population-based register studies have the advantage of large sample sizes and low dropout rates during long-term follow-up. Recent findings from population-based register studies on the efficacy of lithium have supplemented findings from randomized trials and generalized these to all patients with bipolar disorder. Findings from population-based register studies show that (1) half of patients with bipolar disorder continue to take lithium for longer than 6 months, (2) early start of lithium maintenance treatment following the first single manic episode improves the long-term outcome, (3) maintenance treatment with lithium seems to be in general superior to treatment with valproate and lamotrigine, (4) lithium may reduce the risk of suicide and dementia, and (5) lithium-induced end-stage renal disease is rare with modern lithium treatment within recommended serum levels. Based on the accumulated evidence, lithium should be used as first-line maintenance treatment for bipolar disorder and with intensified group-based psychoeducation following onset of first manic episode/bipolar disorder to improve long-term adherence to lithium, especially among younger patients.
Literatur
1.
Zurück zum Zitat Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156(1):5–10.PubMedCrossRef Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156(1):5–10.PubMedCrossRef
2.
Zurück zum Zitat Baldessarini RJ. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs. 2002;16(11):721–9.PubMedCrossRef Baldessarini RJ. Treatment research in bipolar disorder: issues and recommendations. CNS Drugs. 2002;16(11):721–9.PubMedCrossRef
3.
Zurück zum Zitat Reed C, Novick D, Gonzalez-Pinto A, Bertsch J, Haro JM. Observational study designs for bipolar disorder—what can they tell us about treatment in acute mania? Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(4):715–21.PubMedCrossRef Reed C, Novick D, Gonzalez-Pinto A, Bertsch J, Haro JM. Observational study designs for bipolar disorder—what can they tell us about treatment in acute mania? Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(4):715–21.PubMedCrossRef
4.
Zurück zum Zitat Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469–73.PubMedCrossRef Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469–73.PubMedCrossRef
5.
Zurück zum Zitat Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry. 2003;64(9):1091–3.PubMedCrossRef Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry. 2003;64(9):1091–3.PubMedCrossRef
6.
Zurück zum Zitat Partonen T, Sihvo S, Lonnqvist JK. Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry. 1996;57(12):572–5.PubMedCrossRef Partonen T, Sihvo S, Lonnqvist JK. Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry. 1996;57(12):572–5.PubMedCrossRef
7.
Zurück zum Zitat Reinares M, Vieta E, Colom F, Martinez-Aran A, Torrent C, Comes M, et al. Impact of a psychoeducational family intervention on caregivers of stabilized bipolar patients. Psychother Psychosom. 2004;73(5):312–9.PubMedCrossRef Reinares M, Vieta E, Colom F, Martinez-Aran A, Torrent C, Comes M, et al. Impact of a psychoeducational family intervention on caregivers of stabilized bipolar patients. Psychother Psychosom. 2004;73(5):312–9.PubMedCrossRef
8.
Zurück zum Zitat Henry C, Andreassen OA, Barbato A, Demotes-Mainard J, Goodwin GM, Leboyer M, et al. A network to foster research and promote innovative care. Int J Bipolar Disord. 2013;1:2.PubMedCentralPubMedCrossRef Henry C, Andreassen OA, Barbato A, Demotes-Mainard J, Goodwin GM, Leboyer M, et al. A network to foster research and promote innovative care. Int J Bipolar Disord. 2013;1:2.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385–95.PubMedCrossRef Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385–95.PubMedCrossRef
10.
Zurück zum Zitat Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.PubMedCrossRef Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14(3):154–219.PubMedCrossRef
11.
Zurück zum Zitat Calabrese JR, Kemp DE. Bipolar drug development: are we getting closer to the real world? Am J Psychiatry. 2008;165(10):1234–6.PubMedCrossRef Calabrese JR, Kemp DE. Bipolar drug development: are we getting closer to the real world? Am J Psychiatry. 2008;165(10):1234–6.PubMedCrossRef
12.
Zurück zum Zitat Lauer MS, Collins FS. Using science to improve the nation’s health system: NIH’s commitment to comparative effectiveness research. JAMA. 2010;303(21):2182–3.PubMedCrossRef Lauer MS, Collins FS. Using science to improve the nation’s health system: NIH’s commitment to comparative effectiveness research. JAMA. 2010;303(21):2182–3.PubMedCrossRef
13.
Zurück zum Zitat Munk-Jorgensen P, Kastrup M, Mortensen PB. The Danish psychiatric register as a tool in epidemiology. Acta Psychiatr Scand Suppl. 1993;370:27–32.PubMedCrossRef Munk-Jorgensen P, Kastrup M, Mortensen PB. The Danish psychiatric register as a tool in epidemiology. Acta Psychiatr Scand Suppl. 1993;370:27–32.PubMedCrossRef
14.
Zurück zum Zitat Munk-Jorgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44(1):82–4.PubMed Munk-Jorgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull. 1997;44(1):82–4.PubMed
15.
Zurück zum Zitat Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health. 2011;39(7 Suppl):54–7.PubMedCrossRef Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health. 2011;39(7 Suppl):54–7.PubMedCrossRef
16.
Zurück zum Zitat Allebeck P. The use of population based registers in psychiatric research. Acta Psychiatr Scand. 2009;120(5):386–91.PubMedCrossRef Allebeck P. The use of population based registers in psychiatric research. Acta Psychiatr Scand. 2009;120(5):386–91.PubMedCrossRef
17.
Zurück zum Zitat Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349–52.PubMed Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349–52.PubMed
18.
Zurück zum Zitat Malhi GS. The king is dead, long live the king! The restoration of BALANCE. Bipolar Disord. 2010;12(7):681–4.PubMedCrossRef Malhi GS. The king is dead, long live the king! The restoration of BALANCE. Bipolar Disord. 2010;12(7):681–4.PubMedCrossRef
19.
Zurück zum Zitat Ghaemi SN. From BALANCE to DSM-5: taking lithium seriously. Bipolar Disord. 2010;12(7):673–7.PubMedCrossRef Ghaemi SN. From BALANCE to DSM-5: taking lithium seriously. Bipolar Disord. 2010;12(7):673–7.PubMedCrossRef
20.
Zurück zum Zitat Coryell W. Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord. 2009;11 Suppl 2:77–83.PubMedCrossRef Coryell W. Maintenance treatment in bipolar disorder: a reassessment of lithium as the first choice. Bipolar Disord. 2009;11 Suppl 2:77–83.PubMedCrossRef
21.
Zurück zum Zitat Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry. 1998;155(1):30–5.PubMedCrossRef Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry. 1998;155(1):30–5.PubMedCrossRef
22.
Zurück zum Zitat Goodwin FK, Jamison KR. Manic-depressive illness. Oxford: Oxford University Press; 1990. Goodwin FK, Jamison KR. Manic-depressive illness. Oxford: Oxford University Press; 1990.
23.
Zurück zum Zitat Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105(3):164–72.PubMedCrossRef Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105(3):164–72.PubMedCrossRef
24.
Zurück zum Zitat Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord. 1990;18(4):259–66.PubMedCrossRef Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord. 1990;18(4):259–66.PubMedCrossRef
25.
Zurück zum Zitat Berghofer A, Kossmann B, Muller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand. 1996;93(5):349–54.PubMedCrossRef Berghofer A, Kossmann B, Muller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand. 1996;93(5):349–54.PubMedCrossRef
26.
Zurück zum Zitat Schumann C, Lenz G, Berghofer A, Muller-Oerlinghausen B. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res. 1999;89(3):247–57.PubMedCrossRef Schumann C, Lenz G, Berghofer A, Muller-Oerlinghausen B. Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients. Psychiatry Res. 1999;89(3):247–57.PubMedCrossRef
27.
Zurück zum Zitat Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 1996;153(8):993–1000.PubMedCrossRef Johnson RE, McFarland BH. Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry. 1996;153(8):993–1000.PubMedCrossRef
28.
Zurück zum Zitat Kessing LV, Sondergard L, Kvist K, Andersen PK. Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study. Bipolar Disord. 2007;9(7):730–6.PubMedCrossRef Kessing LV, Sondergard L, Kvist K, Andersen PK. Adherence to lithium in naturalistic settings: results from a nationwide pharmacoepidemiological study. Bipolar Disord. 2007;9(7):730–6.PubMedCrossRef
29.
Zurück zum Zitat Kessing LV, Hansen HV, Christensen EM, Dam H, Gluud C, Wetterslev J. Do young adults with bipolar disorder benefit from early intervention? J Affect Disord. 2014;152–154:403–8.PubMedCrossRef Kessing LV, Hansen HV, Christensen EM, Dam H, Gluud C, Wetterslev J. Do young adults with bipolar disorder benefit from early intervention? J Affect Disord. 2014;152–154:403–8.PubMedCrossRef
30.
Zurück zum Zitat Kessing LV, Hansen HV, Hvenegaard A, Christensen EM, Dam H, Gluud C, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry. 2013;202:212–9.PubMedCrossRef Kessing LV, Hansen HV, Hvenegaard A, Christensen EM, Dam H, Gluud C, et al. Treatment in a specialised out-patient mood disorder clinic v. standard out-patient treatment in the early course of bipolar disorder: randomised clinical trial. Br J Psychiatry. 2013;202:212–9.PubMedCrossRef
31.
Zurück zum Zitat Berghofer A, Alda M, Adli M, Baethge C, Bauer M, Bschor T, et al. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry. 2008;69(12):1860–8.PubMedCrossRef Berghofer A, Alda M, Adli M, Baethge C, Bauer M, Bschor T, et al. Long-term effectiveness of lithium in bipolar disorder: a multicenter investigation of patients with typical and atypical features. J Clin Psychiatry. 2008;69(12):1860–8.PubMedCrossRef
32.
Zurück zum Zitat Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord. 2005;7(5):404–17.PubMedCrossRef Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord. 2005;7(5):404–17.PubMedCrossRef
33.•
Zurück zum Zitat Kessing LV, Hellmund G, Andersen PK. Predictors of excellent response to lithium: results from a nationwide register-based study. Int Clin Psychopharmacol. 2011;26(6):323–8. This study identifies predictors of lithium response in a nationwide population.PubMedCrossRef Kessing LV, Hellmund G, Andersen PK. Predictors of excellent response to lithium: results from a nationwide register-based study. Int Clin Psychopharmacol. 2011;26(6):323–8. This study identifies predictors of lithium response in a nationwide population.PubMedCrossRef
34.
Zurück zum Zitat Rybakowski JK. Factors associated with lithium efficacy in bipolar disorder. Harv Rev Psychiatry. 2014;22(6):353–7.PubMedCrossRef Rybakowski JK. Factors associated with lithium efficacy in bipolar disorder. Harv Rev Psychiatry. 2014;22(6):353–7.PubMedCrossRef
35.
Zurück zum Zitat Berk M, Berk L, Dodd S, Cotton S, Macneil C, Daglas R, Conus P, Bechdolf A, Moylan S, Malhi GS: Stage managing bipolar disorder. Bipolar Disord 2013. Berk M, Berk L, Dodd S, Cotton S, Macneil C, Daglas R, Conus P, Bechdolf A, Moylan S, Malhi GS: Stage managing bipolar disorder. Bipolar Disord 2013.
36.
37.••
Zurück zum Zitat Kessing LV, Vradi E, Andersen PK. Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry. 2014;205(3):214–20. This study is the first to investigate response rates to lithium when started early versus late in bipolar disorder.PubMedCrossRef Kessing LV, Vradi E, Andersen PK. Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry. 2014;205(3):214–20. This study is the first to investigate response rates to lithium when started early versus late in bipolar disorder.PubMedCrossRef
38.
Zurück zum Zitat Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59(10):1175–83.PubMedCrossRef Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr Serv. 2008;59(10):1175–83.PubMedCrossRef
39.
Zurück zum Zitat Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57(5):481–9.PubMedCrossRef Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry. 2000;57(5):481–9.PubMedCrossRef
40.•
Zurück zum Zitat Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry. 2011;199:57–63.PubMedCrossRef Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry. 2011;199:57–63.PubMedCrossRef
41.
Zurück zum Zitat Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392–400.PubMedCrossRef Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003;60(4):392–400.PubMedCrossRef
42.
Zurück zum Zitat Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013–24.PubMedCrossRef Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013–24.PubMedCrossRef
43.
Zurück zum Zitat Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord. 2010;12(5):483–93.PubMedCrossRef Licht RW, Nielsen JN, Gram LF, Vestergaard P, Bendz H. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord. 2010;12(5):483–93.PubMedCrossRef
44.•
Zurück zum Zitat Kessing LV, Hellmund G, Andersen PK. An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol. 2012;26(5):644–52. This study compares long-term effects of maintenance treatment with lithium and lamotrigine in clinical practice.PubMedCrossRef Kessing LV, Hellmund G, Andersen PK. An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacol. 2012;26(5):644–52. This study compares long-term effects of maintenance treatment with lithium and lamotrigine in clinical practice.PubMedCrossRef
45.
Zurück zum Zitat Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.PubMedCrossRef Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646.PubMedCrossRef
46.
Zurück zum Zitat Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry. 2005;62(8):860–6.PubMedCrossRef Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry. 2005;62(8):860–6.PubMedCrossRef
47.
Zurück zum Zitat Sondergard L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2008;10(1):87–94.PubMedCrossRef Sondergard L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide. Bipolar Disord. 2008;10(1):87–94.PubMedCrossRef
48.
Zurück zum Zitat Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ. Clinical risk factors for Alzheimer’s disease: a population-based case-control study. Neurology. 1991;41(9):1393–7.PubMedCrossRef Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ. Clinical risk factors for Alzheimer’s disease: a population-based case-control study. Neurology. 1991;41(9):1393–7.PubMedCrossRef
49.
Zurück zum Zitat Cooper B, Holmes C. Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. Age Ageing. 1998;27(2):181–8.PubMedCrossRef Cooper B, Holmes C. Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. Age Ageing. 1998;27(2):181–8.PubMedCrossRef
50.
Zurück zum Zitat Kessing LV, Olsen EW, Mortensen PB, Andersen PK. Dementia in affective disorder: a case-register study. Acta Psychiatr Scand. 1999;100(3):176–85.PubMedCrossRef Kessing LV, Olsen EW, Mortensen PB, Andersen PK. Dementia in affective disorder: a case-register study. Acta Psychiatr Scand. 1999;100(3):176–85.PubMedCrossRef
51.
Zurück zum Zitat Kessing LV, Nilsson FM. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord. 2003;73(3):261–9.PubMedCrossRef Kessing LV, Nilsson FM. Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord. 2003;73(3):261–9.PubMedCrossRef
52.••
Zurück zum Zitat da Silva J, Goncalves-Pereira M, Xavier M, Mukaetova-Ladinska EB. Affective disorders and risk of developing dementia: systematic review. Br J Psychiatry. 2013;202:177–86. This systematic review and meta-analysis presents pooled data on the association between affective disorders and subsequent dementia.PubMedCrossRef da Silva J, Goncalves-Pereira M, Xavier M, Mukaetova-Ladinska EB. Affective disorders and risk of developing dementia: systematic review. Br J Psychiatry. 2013;202:177–86. This systematic review and meta-analysis presents pooled data on the association between affective disorders and subsequent dementia.PubMedCrossRef
53.
Zurück zum Zitat Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry. 2004;75(12):1662–6.PubMedCentralPubMedCrossRef Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry. 2004;75(12):1662–6.PubMedCentralPubMedCrossRef
54.
Zurück zum Zitat Wu KY, Chang CM, Liang HY, Wu CS, Chia-Hsuan WE, Chen CH, et al. Increased risk of developing dementia in patients with bipolar disorder: a nested matched case-control study. Bipolar Disord. 2013;15(7):787–94.PubMedCrossRef Wu KY, Chang CM, Liang HY, Wu CS, Chia-Hsuan WE, Chen CH, et al. Increased risk of developing dementia in patients with bipolar disorder: a nested matched case-control study. Bipolar Disord. 2013;15(7):787–94.PubMedCrossRef
55.
Zurück zum Zitat Hado-Vieira R, Manji HK, Zarate Jr CA. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 2009;11 Suppl 2:92–109.CrossRef Hado-Vieira R, Manji HK, Zarate Jr CA. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 2009;11 Suppl 2:92–109.CrossRef
56.•
Zurück zum Zitat Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry. 2008;65(11):1331–5. This population based study presents an analytical design aiming to decrease potential confounding by indication in the association between lithium and dementia.PubMedCrossRef Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry. 2008;65(11):1331–5. This population based study presents an analytical design aiming to decrease potential confounding by indication in the association between lithium and dementia.PubMedCrossRef
57.
Zurück zum Zitat Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12(1):87–94.PubMedCrossRef Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12(1):87–94.PubMedCrossRef
58.
Zurück zum Zitat Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198:351–6.PubMedCrossRef Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198:351–6.PubMedCrossRef
59.
Zurück zum Zitat Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer’s disease. Int J Geriatr Psychiatry. 2008;23(7):704–11.PubMedCrossRef Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S. A feasibility and tolerability study of lithium in Alzheimer’s disease. Int J Geriatr Psychiatry. 2008;23(7):704–11.PubMedCrossRef
60.
Zurück zum Zitat Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, et al. Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009;70(6):922–31.PubMedCrossRef Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A, et al. Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009;70(6):922–31.PubMedCrossRef
61.
Zurück zum Zitat Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res. 2013;10(1):104–7.PubMed Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res. 2013;10(1):104–7.PubMed
62.
Zurück zum Zitat Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol. 2014;24(4):540–4.PubMedCrossRef Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. End-stage renal disease associated with prophylactic lithium treatment. Eur Neuropsychopharmacol. 2014;24(4):540–4.PubMedCrossRef
63.
Zurück zum Zitat Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. The impact of modern treatment principles may have eliminated lithium-induced renal failure. J Psychopharmacol. 2014;28(2):151–4.PubMedCrossRef Aiff H, Attman PO, Aurell M, Bendz H, Schon S, Svedlund J. The impact of modern treatment principles may have eliminated lithium-induced renal failure. J Psychopharmacol. 2014;28(2):151–4.PubMedCrossRef
64.
Zurück zum Zitat Werneke U, Ott M, Renberg ES, Taylor D, Stegmayr B. A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatr Scand. 2012;126(3):186–97.PubMedCentralPubMedCrossRef Werneke U, Ott M, Renberg ES, Taylor D, Stegmayr B. A decision analysis of long-term lithium treatment and the risk of renal failure. Acta Psychiatr Scand. 2012;126(3):186–97.PubMedCentralPubMedCrossRef
Metadaten
Titel
Treatment Options in Bipolar Disorder: Lessons from Population-Based Registers with Focus on Lithium
verfasst von
Lars Vedel Kessing, MD, DMSc
Publikationsdatum
01.09.2015
Verlag
Springer International Publishing
Erschienen in
Current Treatment Options in Psychiatry / Ausgabe 3/2015
Elektronische ISSN: 2196-3061
DOI
https://doi.org/10.1007/s40501-015-0047-4

Weitere Artikel der Ausgabe 3/2015

Current Treatment Options in Psychiatry 3/2015 Zur Ausgabe

Anxiety, Obsessive Compulsive and Related Disorders (B Brennan and D Dougherty, Section Editors)

Glutamatergic agents for OCD and related disorders

Schizophrenia and Other Psychotic Disorders (J Csernansky, Section Editor)

Neuromodulation Treatments for Schizophrenia

Child and Adolescent Psychiatry (M DelBello, Section Editor)

Pharmacotherapy for Adolescents with Substance Use Disorders

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.